Buffett’s $19 Billion Oil Bet Looks Like a Fortress
It’s the rare oil major that seems built to outlast cycles, keep the dividend flowing, and, as Warren Buffett clearly believes, keep getting stronger.
The yield is about 4.4%, nearly four times what the S&P 500 pays and on paper that looks tempting, but high yields in energy can be a trap. The difference here is Chevron’s payout isn’t balanced on a knife’s edge.
» Read more about: Buffett’s $19 Billion Oil Bet Looks Like a Fortress »
Read More
This High-Yield Fidelity ETF Is Beating the Market, Here’s Why
Fidelity’s High Dividend ETF (FDVV) is a fund that offers a compelling combination of both current dividend income and growth potential. The fund began in September of 2016 and has delivered a 12.8% lifetime annualized return as well as a steady stream of dividends to its shareholders.
Is the Fidelity High Dividend ETF a good investment to make today,
» Read more about: This High-Yield Fidelity ETF Is Beating the Market, Here’s Why »
Read More
Stock Market in Chaos? 1 High-Yield ETF Could Be a Safe Haven
The stock market has gotten off to an extremely rough start in 2025, with highly-valued stocks suddenly selling off on a variety of worries. Both the NASDAQ and S&P 500 entered corrections, erasing trillions in value from the market’s total capitalizations.
Much of this selloff has been driven by threats of sweeping tariffs that would drastically raise costs for American businesses and spur higher inflation.
» Read more about: Stock Market in Chaos? 1 High-Yield ETF Could Be a Safe Haven »
Read More
This Airline Just Made a Huge Change, Will It Pay Off for Investors?
Southwest Airlines (NYSE:LUV) is one of America’s major air transportation companies. Recently, under pressure to deliver improved value for shareholders and renewed growth, the company announced a slate of changes that could, if successful, increase both its top and bottom lines in the years to come.
Today, let’s take a look at Southwest Airlines to see if LUV is a buy,
» Read more about: This Airline Just Made a Huge Change, Will It Pay Off for Investors? »
Read More
1 Science Powerhouse To Own for the Next Decade
Thermo Fisher Scientific has a knack for thriving even in challenging markets. While the company isn’t entirely immune to today’s global headwinds, slower biopharmaceutical spending, tighter budgets in academic labs, and muted demand in China, it has weathered the storm far better than most of its peers.
The reason?
A combination of unmatched scale,
» Read more about: 1 Science Powerhouse To Own for the Next Decade »
Read MoreThe Burst
How a $300 Mistake Opened a $1 Billion Market
Novo Nordisk, the pharmaceutical giant behind weight-loss blockbusters Ozempic and Wegovy, just let a key patent on semaglutide lapse in Canada because it forgot to pay a routine maintenance fee, the pharmaceutical equivalent of forgetting to renew your car registration.
As a result, generic versions of semaglutide, the active ingredient in both drugs,
» Read more about: How a $300 Mistake Opened a $1 Billion Market »
Read MoreThe Spotlight
Can Ray Dalio’s All-Weather Blueprint Shield Your Portfolio?
When storms hit the financial markets, most investors scramble for cover. But what if you could build a portfolio designed to weather any storm, one that doesn’t flinch when stocks sink, inflation spikes, or economic growth stalls?
That was the question billionaire Ray Dalio sought to answer when he created his now-famous All Weather portfolio,
» Read more about: Can Ray Dalio’s All-Weather Blueprint Shield Your Portfolio? »
Read MoreThe Daily
Bank Of Baroda Q2 Review: Brokerages Turn Bullish On Strong Numbers — Check Target Price
Investec offered a bullish outlook on Bank of Baroda, upgrading its rating from ‘hold’ to ‘buy’ while increasing the target price from Rs 250 to Rs 325.
The firm’s re-rating comes on the back of Bank of Baroda’s strong growth and return on assets, which were supported by low credit cost and an NII-led operating profit beat.